Clinical and analytical validation of FoundationOne®CDx, a comprehensive genomic profiling assay for solid tumors
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Clinical and analytical validation of FoundationOne®CDx, a comprehensive genomic profiling assay for solid tumors
Authors
Keywords
Breast cancer, Cancer treatment, Non-small cell lung cancer, Prostate cancer, Cancer genomics, Colorectal cancer, Cancer detection and diagnosis, Biomarkers
Journal
PLoS One
Volume 17, Issue 3, Pages e0264138
Publisher
Public Library of Science (PLoS)
Online
2022-03-17
DOI
10.1371/journal.pone.0264138
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition
- (2021) Kevin Litchfield et al. CELL
- High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types
- (2021) D.J. McGrail et al. ANNALS OF ONCOLOGY
- The current landscape of the FDA approved companion diagnostics
- (2021) Jan Trøst Jørgensen Translational Oncology
- Patient with Lobular Carcinoma of the Breast and Activating AKT1 E17K Variant
- (2021) Harsha Trivedi et al. Acta medica academica
- An overview of precision oncology basket and umbrella trials for clinicians
- (2020) Jay J. H. Park et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials
- (2020) David S Hong et al. LANCET ONCOLOGY
- Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial
- (2020) Michael J Pishvaian et al. LANCET ONCOLOGY
- Systematic dissection of biases in whole-exome and whole-genome sequencing reveals major determinants of coding sequence coverage
- (2020) Yury A. Barbitoff et al. Scientific Reports
- Molecular profiling for precision cancer therapies
- (2020) Eoghan R. Malone et al. Genome Medicine
- Challenges in the clinical implementation of precision medicine companion diagnostics
- (2020) Peter Keeling et al. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
- Targeted PCR vs NGS for molecular diagnostic in solid tumors and liquid biopsies. How to choose in real-life.
- (2020) Jean-Louis Merlin et al. JOURNAL OF CLINICAL ONCOLOGY
- Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
- (2020) Ghassan K Abou-Alfa et al. LANCET ONCOLOGY
- Olaparib for Metastatic Castration-Resistant Prostate Cancer
- (2020) Johann de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project
- (2020) Diana M Merino et al. Journal for ImmunoTherapy of Cancer
- Retrospective analysis of real-world data to determine clinical outcomes of patients with advanced non-small cell lung cancer following cell-free circulating tumor DNA genomic profiling
- (2020) Russell Madison et al. LUNG CANCER
- Identification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors
- (2020) Ole Gjoerup et al. AAPS Journal
- Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
- (2020) Aurélien Marabelle et al. LANCET ONCOLOGY
- Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer
- (2020) Jürgen Wolf et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinicopathologic, genomic and protein expression characterization of 356 ROS1 fusion driven solid tumors cases
- (2020) Richard S. P. Huang et al. INTERNATIONAL JOURNAL OF CANCER
- Defining Clinical Utility of Tumor Biomarker Tests: A Clinician's Viewpoint
- (2020) Daniel F. Hayes JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer
- (2020) Thierry André et al. NEW ENGLAND JOURNAL OF MEDICINE
- Should next-generation sequencing tests be performed on all cancer patients?
- (2019) Andrew J. McKenzie et al. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
- Implementing Precision Medicine in Community-Based Oncology Programs: Three Models
- (2019) Laura A. Levit et al. Journal of Oncology Practice
- Hybrid Capture‐Based Genomic Profiling Identifies BRAF V600 and Non‐V600 Alterations in Melanoma Samples Negative by Prior Testing
- (2019) Lise Boussemart et al. ONCOLOGIST
- A Canadian guideline on the use of next-generation sequencing in oncology
- (2019) S. Yip et al. Current Oncology
- Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non–Small Cell Lung Cancer Using a Clinicogenomic Database
- (2019) Gaurav Singal et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study
- (2019) Jason K. Sicklick et al. NATURE MEDICINE
- Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer
- (2019) Fabrice André et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Novel Next-Generation Sequencing Approach to Detecting Microsatellite Instability and Pan-Tumor Characterization of 1000 Microsatellite Instability–High Cases in 67,000 Patient Samples
- (2019) Sally E. Trabucco et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls
- (2019) James P. Solomon et al. MODERN PATHOLOGY
- How liquid biopsies can change clinical practice in oncology
- (2019) G Siravegna et al. ANNALS OF ONCOLOGY
- U.S. Food and Drug Administration anticancer drug approval trends from 2016 to 2018 for lung, colorectal, breast, and prostate cancer
- (2019) Tatiane Bomfim Ribeiro et al. INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE
- Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
- (2019) Aurelien Marabelle et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence
- (2019) Samuel J. Klempner et al. ONCOLOGIST
- Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors
- (2019) Neil Vasan et al. SCIENCE
- Cancer patients' expectations when undergoing extensive molecular diagnostics—A qualitative study
- (2019) Amy Rohrmoser et al. PSYCHO-ONCOLOGY
- Measuring coverage and accuracy of whole-exome sequencing in clinical context
- (2018) Sek Won Kong et al. GENETICS IN MEDICINE
- Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
- (2018) Alexander Drilon et al. NEW ENGLAND JOURNAL OF MEDICINE
- A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal
- (2018) James X. Sun et al. PLoS Computational Biology
- Assessment of Tumor Sequencing as a Replacement for Lynch Syndrome Screening and Current Molecular Tests for Patients With Colorectal Cancer
- (2018) Heather Hampel et al. JAMA Oncology
- Clinical cancer genomic profiling by three-platform sequencing of whole genome, whole exome and transcriptome
- (2018) Michael Rusch et al. Nature Communications
- LBA52Results of the GEOMETRY mono-1 phase II study for evaluation of the MET inhibitor capmatinib (INC280) in patients (pts) with METΔex14 mutated advanced non-small cell lung cancer (NSCLC)
- (2018) J Wolf et al. ANNALS OF ONCOLOGY
- Genetic counselling and testing of susceptibility genes for therapeutic decision-making in breast cancer—an European consensus statement and expert recommendations
- (2018) Christian F. Singer et al. EUROPEAN JOURNAL OF CANCER
- Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
- (2018) Kathleen Moore et al. NEW ENGLAND JOURNAL OF MEDICINE
- NUT Carcinoma: Clinicopathologic features, pathogenesis, and treatment
- (2018) Christopher A. French PATHOLOGY INTERNATIONAL
- Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
- (2018) Razvan Cristescu et al. SCIENCE
- Comprehensive genomic profiling identifies novel NTRK fusions in neuroendocrine tumors
- (2018) Darren S. Sigal et al. Oncotarget
- Budget impact analysis of comprehensive genomic profiling in patients with advanced non-small cell lung cancer
- (2018) James Signorovitch et al. JOURNAL OF MEDICAL ECONOMICS
- Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2
- (2017) Amit M. Oza et al. GYNECOLOGIC ONCOLOGY
- General paucity of genomic alteration and low tumor mutation burden in refractory and metastatic hepatoblastoma: comprehensive genomic profiling study
- (2017) Hwajeong Lee et al. HUMAN PATHOLOGY
- PS04.06 GEOMETRY Mono-1: Phase II, Multicenter Study of MET Inhibitor Capmatinib (INC280) in EGFR wt, MET-dysregulated Advanced NSCLC
- (2017) J. Wolf et al. Journal of Thoracic Oncology
- Clinical Impact of Hybrid Capture–Based Next-Generation Sequencing on Changes in Treatment Decisions in Lung Cancer
- (2017) Anna Belilovski Rozenblum et al. Journal of Thoracic Oncology
- Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Robert L Coleman et al. LANCET
- Comprehensive Genomic Profiling of Esthesioneuroblastoma Reveals Additional Treatment Options
- (2017) Laurie M. Gay et al. ONCOLOGIST
- Rare Tumor Clinic: The University of California San Diego Moores Cancer Center Experience with a Precision Therapy Approach
- (2017) Shumei Kato et al. ONCOLOGIST
- Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
- (2017) Zachary R. Chalmers et al. Genome Medicine
- A Retrospective Analysis of Precision Medicine Outcomes in Patients With Advanced Cancer Reveals Improved Progression-Free Survival Without Increased Health Care Costs
- (2017) Derrick S. Haslem et al. Journal of Oncology Practice
- The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
- (2016) David N. Louis et al. ACTA NEUROPATHOLOGICA
- Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting
- (2016) J. He et al. BLOOD
- NonamplificationERBB2genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies
- (2016) Jeffrey S. Ross et al. CANCER
- Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study
- (2016) Jennifer J. Wheler et al. CANCER RESEARCH
- Use of comprehensive genomic profiling to direct point-of-care management of patients with gynecologic cancers
- (2016) Lorna Rodriguez-Rodriguez et al. GYNECOLOGIC ONCOLOGY
- Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience
- (2016) M. Schwaederle et al. MOLECULAR CANCER THERAPEUTICS
- Broad Detection of Alterations Predicted to Confer Lack of Benefit From EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal Cancer
- (2016) Andrew Rankin et al. ONCOLOGIST
- Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials
- (2016) James H. Suh et al. ONCOLOGIST
- Clinical Actionability of Comprehensive Genomic Profiling for Management of Rare or Refractory Cancers
- (2016) Kim M. Hirshfield et al. ONCOLOGIST
- Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK -Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization
- (2016) Siraj M. Ali et al. ONCOLOGIST
- Statistical Methods for Clinical Validation of Follow-On Companion Diagnostic Devices via an External Concordance Study
- (2016) Meijuan Li Statistics in Biopharmaceutical Research
- Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches
- (2015) A. Drilon et al. CLINICAL CANCER RESEARCH
- On the Road to Precision Cancer Medicine: Analysis of Genomic Biomarker Actionability in 439 Patients
- (2015) M. Schwaederle et al. MOLECULAR CANCER THERAPEUTICS
- Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors
- (2015) G. M. Frampton et al. Cancer Discovery
- Not All Next Generation Sequencing Diagnostics are Created Equal: Understanding the Nuances of Solid Tumor Assay Design for Somatic Mutation Detection
- (2015) Phillip Gray et al. Cancers
- Comprehensive Genomic Profiling of Relapsed and Metastatic Adenoid Cystic Carcinomas by Next-generation Sequencing Reveals Potential New Routes to Targeted Therapies
- (2014) Jeffrey S. Ross et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Genetic and clinical determinants of constitutional mismatch repair deficiency syndrome: Report from the constitutional mismatch repair deficiency consortium
- (2014) Doua Bakry et al. EUROPEAN JOURNAL OF CANCER
- Next-generation sequencing of adrenocortical carcinoma reveals new routes to targeted therapies
- (2014) J S Ross et al. JOURNAL OF CLINICAL PATHOLOGY
- Triple-Negative Breast Cancer Patients Treated at MD Anderson Cancer Center in Phase I Trials: Improved Outcomes with Combination Chemotherapy and Targeted Agents
- (2014) P. Ganesan et al. MOLECULAR CANCER THERAPEUTICS
- Oncogenic Alterations in ERBB2/HER2 Represent Potential Therapeutic Targets Across Tumors From Diverse Anatomic Sites of Origin
- (2014) J. Chmielecki et al. ONCOLOGIST
- Enabling a Genetically Informed Approach to Cancer Medicine: A Retrospective Evaluation of the Impact of Comprehensive Tumor Profiling Using a Targeted Next-Generation Sequencing Panel
- (2014) D. B. Johnson et al. ONCOLOGIST
- Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology
- (2013) Neal I. Lindeman et al. Journal of Thoracic Oncology
- Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
- (2013) Garrett M Frampton et al. NATURE BIOTECHNOLOGY
- Cancer Genome Landscapes
- (2013) B. Vogelstein et al. SCIENCE
- Breaking a Vicious Cycle
- (2013) D. F. Hayes et al. Science Translational Medicine
- How to apply de Bruijn graphs to genome assembly
- (2011) Phillip E C Compeau et al. NATURE BIOTECHNOLOGY
- Fast and accurate long-read alignment with Burrows–Wheeler transform
- (2010) Heng Li et al. BIOINFORMATICS
- Allele-specific copy number analysis of tumors
- (2010) P. Van Loo et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The Sequence Alignment/Map format and SAMtools
- (2009) H. Li et al. BIOINFORMATICS
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started